• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study

by MM360 Staff | Nov 8, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

by MM360 Staff | Nov 8, 2025 | Uncategorized

Source: CURE articles Post Content Read More

Darzalex Faspro is first FDA-approved therapy for high-risk smoldering multiple myeloma

by MM360 Staff | Nov 7, 2025 | Uncategorized

The FDA has approved daratumumab and hyaluronidase-fihj monotherapy as treatment for adults with high-risk smoldering multiple myeloma, based on results from the randomized phase 3 AQUILA trial.Daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen), a...

Darzalex Faspro is first FDA-approved therapy for high-risk smoldering multiple myeloma

by MM360 Staff | Nov 7, 2025 | Uncategorized

The FDA has approved daratumumab and hyaluronidase-fihj monotherapy as treatment for adults with high-risk smoldering multiple myeloma, based on results from the randomized phase 3 AQUILA trial.Daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen), a...

FDA speeds development of oral pancreatic cancer treatment

by Marisa Wexler, MS | Nov 7, 2025 | Myeloma News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to daraxonrasib, an oral therapy being developed by Revolution Medicines to treat pancreatic cancer. The FDA gives this designation to experimental medicines designed to treat conditions...
« Older Entries
Next Entries »

Recent Content

  • FDA approves ziftomenib to treat some relapsed leukemia patients
  • (no title)
  • The challenge of non-transplant eligible, newly diagnosed multiple myeloma
  • Camera pill to find pancreatic cancer seeks breakthrough status
  • Camera pill to find pancreatic cancer seeks breakthrough status
  • Tinostamustine named orphan drug for treating malignant gliomas
  • New combination therapy approach may improve ovarian cancer care
  • FDA approves 1st treatment for high-risk smoldering myeloma
  • CAR T-cell therapy candidate yields lasting response in tough lymphoma
  • Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT